Nothing Special   »   [go: up one dir, main page]

Humphreys et al., 2018 - Google Patents

FLIP as a therapeutic target in cancer

Humphreys et al., 2018

View PDF @Full View
Document ID
6388651499453872653
Author
Humphreys L
Espona‐Fiedler M
Longley D
Publication year
Publication venue
The FEBS journal

External Links

Snippet

One of the classic hallmarks of cancer is disruption of cell death signalling. Inhibition of cell death promotes tumour growth and metastasis, causes resistance to chemo‐and radiotherapies as well as targeted agents, and is frequently due to overexpression of …
Continue reading at febs.onlinelibrary.wiley.com (PDF) (other versions)

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/1703—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • A61K38/1709—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/177—Receptors; Cell surface antigens; Cell surface determinants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/19—Cytokines; Lymphokines; Interferons
    • A61K38/21—Interferons [IFN]
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES OR MICRO-ORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or micro-organisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or micro-organisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
    • C12Q1/6876—Hybridisation probes
    • C12Q1/6883—Hybridisation probes for diseases caused by alterations of genetic material
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by the preceding groups
    • G01N33/48—Investigating or analysing materials by specific methods not covered by the preceding groups biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/5005—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates

Similar Documents

Publication Publication Date Title
Humphreys et al. FLIP as a therapeutic target in cancer
Gong et al. The role of necroptosis in cancer biology and therapy
Marchi et al. Akt‐mediated phosphorylation of MICU 1 regulates mitochondrial Ca2+ levels and tumor growth
Galluzzi et al. Necroptosis: mechanisms and relevance to disease
Matt et al. The DNA damage-induced cell death response: a roadmap to kill cancer cells
Xi et al. The role of interaction between autophagy and apoptosis in tumorigenesis
Xu et al. Cisplatin-induced necroptosis in TNFα dependent and independent pathways
Herr et al. Cellular stress response and apoptosis in cancer therapy
Plati et al. Apoptotic cell signaling in cancer progression and therapy
ES2705237T3 (en) Method for diagnosis and prognosis of lung cancer metastasis
Seo et al. The roles of ubiquitination in extrinsic cell death pathways and its implications for therapeutics
Fennell et al. Defective core-apoptosis signalling in diffuse malignant pleural mesothelioma: opportunities for effective drug development
Lin et al. Induction of Cbl‐dependent epidermal growth factor receptor degradation in Ling Zhi‐8 suppressed lung cancer
Kim et al. Association of aminoacyl-tRNA synthetases with cancer
EP3049521A1 (en) Compounds for inducing anti-tumor immunity and methods thereof
Ivanova et al. Regulation of death receptor signaling by the autophagy protein TP 53 INP 2
Kulbay et al. Review of cancer cell resistance mechanisms to apoptosis and actual targeted therapies
Davidson et al. 3q26‐29 Amplification in head and neck squamous cell carcinoma: a review of established and prospective oncogenes
Cheng et al. ABT‑737, a Bcl‑2 family inhibitor, has a synergistic effect with apoptosis by inducing urothelial carcinoma cell necroptosis
Watson et al. Antifibrotic Drug Nintedanib Inhibits CSF1R to Promote IL-4–associated Tissue Repair Macrophages
Seidelin Regulation of antiapoptotic and cytoprotective pathways in colonic epithelial cells in ulcerative colitis
Yang et al. Role of gasdermin family proteins in cancers
KR20230017167A (en) Methods and compositions for treating cancer
Hassan et al. Fas‐induced apoptosis of renal cell carcinoma is mediated by apoptosis signal‐regulating kinase 1 via mitochondrial damage‐dependent caspase‐8 activation
Wang et al. Differential phosphoprotein levels and pathway analysis identify the transition mechanism of LNCaP cells into androgen‐independent cells